Researchers from all over the world have been working tirelessly to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic since the World Health Organization (WHO) proclaimed it to be a pandemic in 2019. Expanding testing capacities, creating efficient medications, and creating safe and efficient COVID-19 (SARS CoV-2) vaccinations that provide the human body with long-lasting protection are a few tactics that need to be investigated. In clinical studies, drug delivery techniques, including nanoparticles, have been used since the early 1990s. Since then, as technology has advanced and the need for improved medication delivery has increased, the field of nanomedicine has recently seen significant development. PNPs, or polymeric nanoparticles, are solid particles or particulate dispersions that range in size from 10 to 1000 nm, and their ability to efficiently deliver therapeutics to specific targets makes them ideal drug carriers. This review article discusses the many polymeric nanoparticle (PNP) platforms developed to counteract the recent COVID-19 pandemic-related severe acute respiratory syndrome coronavirus (SARS-CoV-2). The primary subjects of this article are the size, shape, cytotoxicity, and release mechanism of each nanoparticle. The two kinds of preparation methods in the synthesis of polymeric nanoparticles have been discussed: the first group uses premade polymers, while the other group depends on the direct polymerization of monomers. A few of the PNPs that have been utilized to combat previous viral outbreaks against SARS-CoV-2 are also covered.

With the progress of science and technology, the research and development of silver nanoparticles has also developed. This paper attempts to prepare a silver nanoparticle by electrolyzing AgNO3 solution with electrochemical reduction method and citric acid as a complexing agent in a certain current and time. The crystal morphology and sample purity of silver nanoparticles were analyzed by X-ray diffractometer. The crystal structure of the nanoparticles was analyzed by scanning electron microscopy (SEM). The crystal structure of the nanoparticles was analyzed by X-ray diffraction. The particle size distribution of the particles was in the range of 125-199 nm, and the carbon paste electrode was modified with the prepared silver nanoparticles. The electrocatalytic activity of the carbon paste electrode was preliminarily explored.

According to the World Health Organization (WHO), breast cancer is among the most common cancers worldwide. Most of the anticancer agents have been showing a variety of side effects. Recently, bacterial proteins have been investigated as promising anticancer agents. Azurin is a bacterial cupredoxin protein secreted from Pseudomonas aeruginosa and has been reported as a potent multi-targeting anticancer agent, which makes it an appropriate candidate for drug delivery. Azurin may be delivered to cancer cells using different carriers like polymeric micro and nanoparticles. In the present study, azurin was extracted from the bacterial host and loaded into chitosan particles. Then its effect on MCF-7 cell line was investigated. Chitosan-azurin particles were made using the ion gelation method. Results showed that chitosan-azurin particles are about 200 nm, and the loading of the protein in particles did not affect its integrity. The MTT assay showed a significant reduction in cell viability in azurin and chitosan-azurin-treated cells. The toxicity level after 5 days was 63.78% and 82.53% for free azurin and chitosan-azurin-treated cells, respectively. It seems using an appropriate carrier system for anticancer proteins like azurin is a promising tool for developing low side effect anticancer agents.

This work shows the results of the biosynthesis of silver nanoparticles using the microalga Chlorella sp, using growth media with different concentrations of glycerol, between 5%–20%, and different light and temperature conditions. The synthesis of nanoparticles was studied using supernatants and pellets from autotrophic, heterotrophic and mixotrophic cultures of the microalga. The presence of nanoparticles was verified by ultraviolet-visible spectroscopy and the samples showing the highest concentration of nanoparticles were characterized by scanning electron microscopy. The mixotrophic growth conditions favored the excretion of exopolymers that enhanced the reduction of silver and thus the formation of nanoparticles. The nanoparticles obtained presented predominantly ellipsoidal shape with dimensions of 108 nm × 156 nm and 87 nm × 123 nm for the reductions carried out with the supernatants of the mixotrophic cultures with 5% and 10% glycerol, respectively.

Zero-valent iron is a moderately reducing reagent that is both non-toxic and affordable. In the present work, iron nanoparticles were synthesized using bitter guard leaf extract (Momordica charantia L.) (BGL-Fe NP). Using leaf samples from bitter protectant extract, iron nanoparticles were synthesized with secondary metabolites such as flavonoids and polyphenols acting as capping and reducing agents. Polyphenols reduce Fe²⁺/Fe³⁺ to nanovalent iron or iron nanoparticles. Iron nanoparticles were synthesized by reducing iron chloride as a precursor with bitter protective leaf extract in an alkaline environment. The obtained BGL-Fe NPs were calcined for 4 h at various temperatures of 400 °C, 500 °C, and 600 °C. The obtained samples were coded as BGL-Fe NPs-4, BGL-Fe NPs-5, and BGL-Fe NPs-6, respectively. The synthesized BGL-Fe NPs were systematically characterized by XRD, SEM, FTIR, UV-Vis and TG-DTA analysis. The obtained BGL-Fe NPs were then used as an adsorbent to remove the aqueous solution of basic methylene blue (MB) dye. MB concentration was monitored using UV-Vis spectroscopy.

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. Cisplatin-loaded nanoparticle formulations were optimized utilizing response surface methods and the central composite rotating design model. This study employed a central composite rotatable design with a three-factored factorial design with three tiers. Three independent variables namely drug polymer ratio, aqueous organic phase ration, and stabilizer concentration were used to examine the particle size, entrapment efficiency, and drug loading of cisplatin PLGA nanoparticles as responses. The results revealed that this response surface approach might be able to be used to find the best formulation for the cisplatin PLGA nanoparticles. A polymer ratio of 1:8.27, organic phase ratio of 1:6, and stabilizer concentration of 0.15 were found to be optimum for cisplatin PLGA nanoparticles. Nanoparticles made under the optimal conditions found yielded a 112 nm particle size and a 95.4 percent entrapment efficiency, as well as a drug loading of 9 percent. The cisplatin PLGA nanoparticles tailored for scanning electon microscopy displayed a spherical form. A series of in vitro tests showed that the nanoparticle delivered cisplatin progressively over time. According to this work, the Response Surface Methodology (RSM) employing the central composite rotatable design may be successfully used to simulate cisplatin-PLGA nanoparticles.